Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits.
about
Therapeutic drug monitoring of antiretrovirals for people with HIVNeuroprotection mediated by inhibition of calpain during acute viral encephalitisDrug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxisShort-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement.A critical evaluation of the therapeutic range of indinavir.Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma.Early factors in successful anti-HIV treatment.Drug interactions in the management of HIV infection.Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteersEffect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers.The role of cytochrome P450 in antiretroviral drug interactions.Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.Pharmacokinetic drug interactions involving Ginkgo biloba.Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease.Mechanisms and Consequences of Drug-Drug Interactions.Identification of degradation products of saquinavir mesylate by ultra-high-performance liquid chromatography/electrospray ionization quadrupole time-of-flight tandem mass spectrometry and its application to quality control.96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients.The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464: a novel generation of nonnucleoside inhibitors.Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells.Inhaled fluticasone causes iatrogenic cushing's syndrome in patients treated with Ritonavir.Modulation of the LDL receptor and LRP levels by HIV protease inhibitors.Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats.Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.Bacterial proteases: current therapeutic use and future prospects for the development of new antibiotics
P2860
Q24239932-103A1CAF-E532-4040-9557-42452557DA4BQ26700065-4FBA96D0-C491-40C8-8A45-9D1662D640DEQ28486428-C8700C5C-D748-4EE1-9E06-7CC5EA7168E0Q33148910-305A9533-DCDA-4253-B4A6-9F90A86A6EACQ33983571-BD0A2012-D0C8-4276-8273-54C2C4FC6BF9Q34253139-DDBA3A73-0105-408F-8F37-45C4316AD5D6Q34521994-8F3BF8DB-8F05-4527-BCEE-716262793FDBQ34709881-961AD1A0-4390-46FE-8695-02EFD00B06A8Q35103600-B2ABDFA0-D229-4344-BF96-11515F8C2100Q35207282-4C94EC34-7028-42F3-850C-FF3A9931126EQ36066083-3A045F87-F63B-4038-BB97-361860DF9BC8Q36558221-5411EDCA-E585-41FC-8208-33C8365D3D58Q36593820-3D483F09-C034-479A-9DB7-9F5C5C3569F9Q36909336-9CEAD9B5-D6EF-4199-A123-716893C79BD1Q37383940-3A846C87-44FF-4A00-B94F-6A09EE6F6B9BQ37598680-CF81DAB2-A4BB-4106-94AE-52D0428299F1Q38122439-DAC82191-0CAD-482D-B6C9-53BE30A8B0FDQ38123911-2E042CD7-838A-4CA4-BC21-9D565BC009E9Q40306549-DAC8ACCA-F505-47A5-A822-D76D9C08C4DEQ40319163-CD7B285A-AA8C-43F2-A581-89B2B72F5F39Q43195216-97B275A6-BA97-4AEE-90F2-FDA86A724153Q43747959-0B904DD0-3B50-4180-A753-BB13C9769D2DQ43930852-7D116F2D-836A-474D-B026-89573BCD3BEBQ44013360-86F46BCA-D49D-4632-BF11-A9BEB08E13AEQ44499492-A8D95330-A83D-4556-9CDA-46F2481A3879Q44777237-896AB393-9A85-42C9-AA60-DB22A1915993Q46582815-CEC23F2A-E637-44C7-BE6D-0B01947F309BQ58863313-7623DDB2-17AA-410E-AF98-661B427A0754
P2860
Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Dual protease inhibitor therap ...... tionale and clinical benefits.
@ast
Dual protease inhibitor therap ...... tionale and clinical benefits.
@en
type
label
Dual protease inhibitor therap ...... tionale and clinical benefits.
@ast
Dual protease inhibitor therap ...... tionale and clinical benefits.
@en
prefLabel
Dual protease inhibitor therap ...... tionale and clinical benefits.
@ast
Dual protease inhibitor therap ...... tionale and clinical benefits.
@en
P1476
Dual protease inhibitor therap ...... tionale and clinical benefits.
@en
P2093
P304
P356
10.1146/ANNUREV.PHARMTOX.40.1.649
P577
2000-01-01T00:00:00Z